Table 1.
Author | Year | Subjects | No. Pts. | No. Eyes | Treatment | Patient Survival | Overall OS | Primary Enuc | Secondary OS |
---|---|---|---|---|---|---|---|---|---|
Reese | 1949 | bl | 53 | 106 | enuc advanced, EBR less advanced | 41/53 (77%) | 43/106 (41%) | 53/106 (50%) | 40/53 (75%) |
Abramson | 1979 | bl | 24 | 48 | bl enuc | 19/24 (80%) | 0% | 48/48 (100%) | 0% |
Gagnon | 1980 | bl | 25 | 50 | enuc advanced, EBR if less advanced | 67.6% at 5 yrs | 22/50 (44%) | 22/50 (50%) | 22/28 (79%) |
Abramson | 1981 | RE IV or V | 32 | 64 | bilateral EBR | 28/32 (88%) | 19/64 (30%) | NR | 19/64 (30%) |
Abramson | 1981 | RE I to III | 37 | 74 | bilateral EBR | 30/32 (94%) | 63/74 (85%) | NR | 63/74 (85%) |
Haye | 1987 | bl rb eye RE V) | 33 | 66 | systemic chemo, EBR | 15/23 (63%) | NR | 18/66 (27%) | 7/21 (33%) |
Kingston | 1996 | RE V | 14 | 28 | systemic chemo, EBR | 12/14 (86%) | 17/28 (61%) | 4/28 (14%) | 17/24 (71%) |
Gallie | 1996 | bl | 31 | 62 | chemoreduction | 30/31 (97%) | 38/62 (61%) | 22/62 (35%) | 38/40 (95%) |
Lee | 2003 | bl, one eye enuc | 107 | 107 | systemic chemo, radiation, focal | 100/108 (93%) | 72/214 (34%) | 107/214 (50%) | 72/107 (67%) |
Sohajda | 2006 | bl, one eye enuc | 13 | 26 | systemic chemo, brachy | 12/13 (93%) | 12/26 (46%) | 13/26 (50%) | 12/13 (93%) |
Berry | 2013 | bl, only IC D | 49 | 62 | systemic chemo, IMRT, brachy, focal | NR | NA | NA | 45/55 (82%) |
Francis | 2018 | bl | 46 | 92 | majority OAC | 41/42 (98%) | 84/92 (91%) | 7/92 (7.6%) | 83/84 (99%) |
No., number; Pts., patients; Enuc, enucleation; bl, bilateral; brachy, brachytherapy; IMRT, intense modulated radiation therapy; yrs, years; mos, months; NR, not recorded; NA, insufficient data on fellow eyes.